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0.610 for typical adherence, and 0.441 for ideal adherence.
Mean life expectancy was 14.73 years for no treatment, 15.07
years for typical adherence, and 15.49 for ideal adherence. The
incremental cost effectiveness ratio per life-year gained was
$30,585 between typical adherence and no treatment, and
$22,121 between ideal adherence and typical adherence. CON-
CLUSION: Nonadherence to lipid-lowering and antihyperten-
sive therapy contributes signiﬁcantly to the clinical and economic
burden of heart disease and stroke in the population considered.
Patients with typical adherence levels receive approximately
50% of the risk reduction seen in clinical trials with controlled
levels of ideal adherence.
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OBJECTIVES: To determine the cost-effectiveness of providing
aspirin, low molecular weight heparin (LMWH), or compression
stockings to air travelers for the prevention of air traveler throm-
bosis (ATT). METHODS: A pharmacoeconomic model was con-
structed from the perspective of a 1.5 million member US
managed care organization (MCO). The model had a one-year
time horizon to coincide with typical budgetary cycles. Air travel
estimates were calculated using 2005 Federal Aviation Adminis-
tration and US Census Bureau statistics. Published ATT inci-
dence estimates varied across patient risk factors and distance
ﬂown, ranging from zero to 455 events per 100,000 ﬂights.
Treatment efﬁcacy estimates for the relative risk reduction of
ATT during and immediately following air travel were obtained
from published literature. The model assumed prophylactic
therapy use prior to each ﬂight; for compression stockings, one
set was issued per patient for all ﬂights. Cost inputs included
medical charges for incident ATT treatment (extrapolated from
the literature) and prophylactic treatments (estimated from
wholesale acquisition costs). Five reiterations of the model were
performed to test all ATT incidence estimates. Incremental cost-
effectiveness ratios (ICERs) were calculated for prophylaxis
versus no treatment. RESULTS: In 4 of 5 risk scenarios, ICERs
for aspirin prophylaxis was dominant, with potential MCO cost
savings ranging from $436,700 to $1,251,500. For compression
stockings, ICERs were dominant for patients taking long-haul
ﬂights only (>5000 miles), with potential cost savings of
$957,700 to $1,141,600. LMWH prophylaxis did not result in
cost savings under any scenario. Reducing the treatment efﬁcacy
estimates by up to 20% did not alter these results. CONCLU-
SION: Payment for prophylactic aspirin therapy for ATT pre-
vention in air travelers resulted in cost savings for a MCO, as
did payment for compression stockings for use during long-haul
ﬂights. MCOs that develop programs to provide prophylactic
therapies to air travelers could realize signiﬁcant cost savings.
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OBJECTIVES: Pharmacoeconomic analysis of extended pre-
ventive injection of enoxaparin after hip joint replacement 
and costing of one prevented case of deep venous thrombosis
(DVT) in the enoxaparin group compared to placebo in Russia.
METHODS: The pharmacoeconomic analysis was based on the
results of prospective, randomized, double controlled study of
the use of enoxaparin as extended DVT prophylaxis conducted
in a clinical center in Sweden (Bergqvist D. et al., 1996). The efﬁ-
ciency of extended prophylaxis by enoxaparin versus placebo in
hospital environment was studied during the trial. All patients
(n = 262) received a daily hypodermic injection of 40 mg of
enoxaparin after preventative hip joint replacement, on average
during 9 days of their hospitalization (open study period). After
that the patients were randomized in groups. 131 patients in the
placebo group and 131 patients in the enoxaparin group received
the treatment. It was suggested that the patients of both groups
be injected with 40 mg of enoxaparin daily, on average during
18.6 days. In the clinical trial the number of detected DVT in
each group was assumed as the most adequate index of efﬁciency.
21 and 45 DVT cases were detected in the enoxaparin and the
placebo group respectively. RESULTS: In Russia total costs of
extended prophylaxis after hip joint replacement in comparison
groups amounted to $186,272 in the enoxaparin group and
$159,584 in the placebo group. Costs per patient amounted to
$1422 in the enoxaparin group and to $1218 in the placebo
group. With the help of efﬁciency increment analysis, the cost of
one DVT case prevented by way of extended prophylaxis by
enoxaparin versus placebo amounted to $1112. CONCLU-
SION: According to the results of the pharmacoeconomic analy-
sis based on the ﬁndings of the clinical trial, the cost of one DVT
case prevented with the help of extended prophylaxis by enoxa-
parin versus placebo is $1112.
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OBJECTIVES: Given the changing statin marketplace, this study
compares the cost-effectiveness among generic statins (lovas-
tatin, pravastatin, simvastatin) and more effective branded
monotherapy statins (atorvastatin, rosuvastatin) for ﬁrst and
second tier placement consideration, respectively, in routine clin-
ical practice. METHODS: Retrospective electronic medical
record database study was conducted of newly prescribed statin
therapy during August 2003–March 2005. Effectiveness of each
statin in reducing LDL-C and attaining National Cholesterol
Education Panel Adult Treatment Panel III LDL-C goal was eval-
uated using multivariate regressions after adjusting for baseline
LDL-C, demographics, comorbidities, and therapy duration.
Cost-effectiveness from a payer perspective was estimated for
rosuvastatin and atorvastatin (branded statins), and separately
for lovastatin, simvastatin and pravastatin (generic statins).
Annualized costs for statin (wholesale acquisition cost, WAC)
and titration were included. RESULTS: Of 10,421 eligible
patients, adjusted LDL-C reduction was signiﬁcantly greater (p
< 0.001) with rosuvastatin (−31.6%) than atorvastatin (−21.9%)
and other generic statins (−19.1% to −13.9%). Average dose of
rosuvastatin was 12 mg vs. 17–35 mg for other statins. Among
patients not at goal at baseline, the adjusted percentage of mod-
erate/high risk patients attaining LDL-C goal was higher (p <
0.001) for rosuvastatin (76.1%) versus atorvastatin (72.6%) and
other statins (57.6%–65%). Rosuvastatin was more effective
and less costly than atorvastatin in terms of cost per patient
reaching goal (in high and moderate risk patients) and in terms
of percent LDL-C lowering. Simvastatin and pravastatin
